Payment overview · 2025
General Payments
$617.49
27 reported records · 9 companies
Healthcare provider profile · identity verified
Casey Edwards, FNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ORANGE PARK, FL · NPI 1245587393
Verified facts
What the public records show
CMS Open Payments records show Casey Edwards, FNP-BC received $617.49 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.29 | 28.2% | 11 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $161.98 | 26.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.68 | 12.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.56 | 11.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.45 | 7.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.71 | 6.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.59 | 3.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.87 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.36 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.49 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $161.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.75 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.75 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.54 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.56 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.32 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.23 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $46.45 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.71 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 28 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 115 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 111 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 40 |
| Gabapentin | Gabapentin | 103 | 45 |
| Losartan Potassium | Losartan Potassium | 96 | 43 |
| Lisinopril | Lisinopril | 83 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 31 |
| Omeprazole | Omeprazole | 72 | 38 |
| Azithromycin | Azithromycin | 71 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 18 |
| Alprazolam | Alprazolam | 66 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 35 |
| Tramadol Hcl | Tramadol Hcl | 63 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 26 |
| Metformin Hcl | Metformin Hcl | 59 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 28 |
| Celecoxib | Celecoxib | 47 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Trazodone Hcl | Trazodone Hcl | 45 | 18 |
| Montelukast Sodium | Montelukast Sodium | 44 | 23 |
| Cefdinir | Cefdinir | 43 | 32 |
| Fluconazole | Fluconazole | 43 | 34 |
| Allopurinol | Allopurinol | 42 | 14 |
| Methocarbamol | Methocarbamol | 41 | 25 |
| Ozempic | Semaglutide | 40 | 12 |
| Simvastatin | Simvastatin | 40 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 38 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 14 |
| Prednisone | Prednisone | 36 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 14 |
| Furosemide | Furosemide | 35 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Buspirone Hcl | Buspirone Hcl | 34 | 14 |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 16 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 14 |
| Methylprednisolone | Methylprednisolone | 31 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Eliquis | Apixaban | 28 | 12 |
| Azelastine Hcl | Azelastine Hcl | 27 | 17 |
| Carvedilol | Carvedilol | 27 | 13 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Meloxicam | Meloxicam | 26 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Ibuprofen | Ibuprofen | 25 | 13 |
| Famotidine | Famotidine | 24 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Glipizide | Glipizide | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | 11 |
| Potassium Chloride | Potassium Chloride | 21 | 11 |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 11 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.49 · 27 records | ABBVIE INC. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, Paradise Ultrasound Renal Denervation System, QULIPTA, Rybelsus, Sunosi, UBRELVY, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error